Global Organ Transplant Immunosuppressant Drugs Market Size, Share & Trends Analysis Report By Drug Class (Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids, and Others), By Transplant Organ (Heart, Kidney, Lung, and Others), By Drug Type (Generic & Branded), Forecast 2020-2026.
The global organ transplant immunosuppressant drug market is anticipated to grow at a CAGR 14% during the forecast period. A wide range of immunosuppressant drugs is used after the organ transplant to reduce the chances of organ rejection by the body. Immunosuppressant drugs also aid in preventing the newly transfer organ form the various infections. Hence, increasing demand for organ transplants across the globe is expected to significantly drive the organ transplant immunosuppressant drug market during the forecast period. However, the high cost of organ transplants and its drugs is one of the major restraints for the market, especially in emerging economies.
The global organ transplant immunosuppressant drugs market is segmented based on the drug class, transplant organ, and drug type. Based on the drug class, the market is sub-segmented into calcineurin inhibitors, antiproliferative agents, mTOR inhibitors, steroids, and others. Further, based on transplant organ, the market is sub-segmented into the heart, kidney, lung, and others. By drug type, the market is bifurcated into generic and patented drugs.
The global organ transplant immunosuppressant drugs market is further segmented based on geography including North America, Europe, Asia-Pacific, and the Rest of the World. North America is expected to have a major market share during the forecast period. It is due to the increasing organ transplant across the region. For instance, according to the United Network for Organ Sharing (UNOS), in 2019, around 40,000 organs were transplanted alone in the US.
The key players of the global organ transplant immunosuppressant drugs market include Astellas Pharma Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Neovii Pharmaceuticals AG, Novartis AG, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including merger, and acquisition, collaborations with government, funding, and new drug launches to stay competitive in the market.
Research Methodology
The market study of the global organ transplant immunosuppressant drugs market is incorporated by extensive primary and secondary research conducted. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook.
In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts to brings added value to the reports.
Secondary Sources Include
The report is intended for the drug manufacturers, hospitals & clinics, and other related industries for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, products offered by the companies, and future market opportunities. The report will serve as a source for a 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.
Market Segmentation
The Report Covers
The global organ transplant immunosuppressant drug market is anticipated to grow at a CAGR 14% during the forecast period. A wide range of immunosuppressant drugs is used after the organ transplant to reduce the chances of organ rejection by the body. Immunosuppressant drugs also aid in preventing the newly transfer organ form the various infections. Hence, increasing demand for organ transplants across the globe is expected to significantly drive the organ transplant immunosuppressant drug market during the forecast period. However, the high cost of organ transplants and its drugs is one of the major restraints for the market, especially in emerging economies.
The global organ transplant immunosuppressant drugs market is segmented based on the drug class, transplant organ, and drug type. Based on the drug class, the market is sub-segmented into calcineurin inhibitors, antiproliferative agents, mTOR inhibitors, steroids, and others. Further, based on transplant organ, the market is sub-segmented into the heart, kidney, lung, and others. By drug type, the market is bifurcated into generic and patented drugs.
The global organ transplant immunosuppressant drugs market is further segmented based on geography including North America, Europe, Asia-Pacific, and the Rest of the World. North America is expected to have a major market share during the forecast period. It is due to the increasing organ transplant across the region. For instance, according to the United Network for Organ Sharing (UNOS), in 2019, around 40,000 organs were transplanted alone in the US.
The key players of the global organ transplant immunosuppressant drugs market include Astellas Pharma Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Neovii Pharmaceuticals AG, Novartis AG, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including merger, and acquisition, collaborations with government, funding, and new drug launches to stay competitive in the market.
Research Methodology
The market study of the global organ transplant immunosuppressant drugs market is incorporated by extensive primary and secondary research conducted. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook.
In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts to brings added value to the reports.
Secondary Sources Include
- Financial reports of companies involved in the market.
- Whitepapers, research-papers, and news blogs.
- Company websites and their product catalog.
The report is intended for the drug manufacturers, hospitals & clinics, and other related industries for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, products offered by the companies, and future market opportunities. The report will serve as a source for a 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.
Market Segmentation
- Global Organ Transplant Immunosuppressant Drugs Market Research and Analysis, By Drug Class
- Global Organ Transplant Immunosuppressant Drugs Market Research and Analysis, By Transplant Organ
- Global Organ Transplant Immunosuppressant Drugs Market Research and Analysis, By Drug Type
The Report Covers
- Comprehensive research methodology of the Global Organ Transplant Immunosuppressant Drugs Market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the Global Organ Transplant Immunosuppressant Drugs Market.
- Insights about market determinants which are stimulating the Global Organ Transplant Immunosuppressant Drugs Industry.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
Table of Contents
1. Report Summary
2. Market Overview and Insights
3. Competitive Landscape
4. Market Determinants
5. Market Segmentation
6. Regional Analysis
7. Company Profiles
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
A selection of companies mentioned in this report includes:
- AbbVie Inc.
- Accord Healthcare Ltd. (Intas Pharmaceuticals Ltd.)
- Allnatt Pharma LLP
- Asahi Kasei Corp.
- Astellas Pharma Inc.
- Biocon Ltd.
- Bristol-Myers Squibb Co.
- Cadila Healthcare Ltd.
- Dr. Reddy’s Laboratories Ltd.
- F. Hoffmann-La Roche Ltd.
- Mylan NV
- Neovii Pharmaceuticals AG
- Novartis AG
- Pfizer Inc.
- Sanofi SA
- Swiss Pharma Pvt. Ltd.
- Teva Pharmaceutical Industries Ltd.
- Veloxis Pharmaceuticals, Inc.
